Psoriasis Clinical Trials in Austin

View 18 new treatments for Psoriasis in Austin, TX, and other areas near me, such as Round Rock. Every day, Power helps hundreds of psoriasis patients connect with leading medical research.
View 19 trials in Austin
Filter (19)

Risankizumab vs Deucravacitinib for Psoriasis

AbbVie Clinic, Cedar Park + 1 more

Psoriasis is a long-term skin disease which causes red, itchy, scaly patches most commonly on the knees, elbows, scalp, and torso (chest, back, and abdomen). In participants with psoriasis, certain skin cells multiply much faster and the skin can develop rough patches that may be red or white with scales. There are many types of psoriasis, but plaque psoriasis is the most common. The exact cause of psoriasis is unknown, but researchers think it may be caused by the body's immune system not working properly. This study is designed to enroll 336 participants 18 years of age and older with have been diagnosed with moderate chronic plaque psoriasis for at least 6 months prior to Baseline (Day 1) and who have not previously been treated with a biologic treatment (natural substance that is made by using living cells in a laboratory). This is a Phase 4, randomized, open-label, assessor blinded, active comparator study with 2 Parts. Phase 4 studies test treatments that have already been approved to treat patients with a condition or disease. This study is open-label, which means that both participants and study doctors know which study treatment is given to participants Participants will be administered subcutaneous (SC) treatment of risankizumab every 12 weeks for up to 44 weeks or provided deucravacitinib oral tablets to be taken once daily. There may be higher treatment burden for participants in this trial compared to their standard of care (due to study procedures). Participants will attend regular (weekly, monthly) visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.Show More
Recruiting

No Placebo Trial

Phase 4
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Austin + 1 more

This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.Show More
Recruiting
Phase 4
Est. 3 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Bimekizumab for Psoriatic Arthritis

UCB Biopharma Clinic, Austin + 1 more

This trial is testing the safety and effectiveness of bimekizumab, a medication given as an injection under the skin. It is aimed at adults who have psoriatic arthritis, a condition that causes joint pain and swelling. Bimekizumab works by blocking proteins that cause inflammation, helping to reduce pain and swelling.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
UCB Cares
Study Director

Tildrakizumab for Psoriatic Arthritis

Sun Clinic, Austin + 1 more

This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team

Apremilast for Pediatric Plaque Psoriasis

Amgen Clinic, Pflugerville + 1 more

The primary objective of this post-marketing study is to assess the safety and tolerability of apremilast in pediatric participants (ages 6 through 17 years) with mild to moderate plaque psoriasis.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 5 - 8 Weeks
MD
Study Director

Risankizumab for Psoriatic Arthritis

AbbVie Clinic, Austin + 1 more

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (PsA).
Waitlist
Phase 3
Est. 5 - 8 Weeks
ABBVIE INC.
Study Director

Deucravacitinib for Psoriasis

Bristol-Myers Squibb Clinic, Pflugerville + 1 more

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have been previously enrolled in an applicable Phase 3 psoriasis study.Show More
Waitlist

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Bristol-Myers Squibb
Study Director

Ixekizumab + Tirzepatide for Psoriasis

Eli Lilly Clinic, Pflugerville + 2 more

The main purpose of this study is to demonstrate that when participants with moderate to severe plaque psoriasis and obesity or overweight in the presence of at least 1 weight-related comorbid condition receive ixekizumab and tirzepatide concomitantly administered, participants see improvement in their psoriasis and achieve weight reduction compared to when receiving ixekizumab. Participation in this study includes up to 12 visits and could last up to 61 weeks including screening, open label treatment period, and post-treatment follow-up period.Show More
Recruiting

No Placebo Trial

Phase 3
Est. 3 - 12 Weeks
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Study Director

Guselkumab for Psoriasis

Janssen Clinic, Pflugerville + 2 more

The purpose of this study is to evaluate the efficacy of guselkumab treatment versus placebo in skin of color participants with predominant moderate-to-severe body psoriasis or predominant moderate-to-severe scalp psoriasis by assessing improvements in the signs and symptoms of psoriasis.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director

Guselkumab for Psoriatic Arthritis

Janssen Clinic, Austin + 1 more

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.Show More
Recruiting
Phase 3
Est. 5 - 8 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 2

Frequently Asked Questions

How much do psoriasis clinical trials pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range. Further, most trials will cover the costs of an Uber to-and-from the clinic. Factors that can affect compensation include the phase of the trial, the length of the trial, the frequency of visits, and the specific condition being studied.

Do I need to be insured to participate in a medical study?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on Cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

How do psoriasis clinical trials work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll typical be sorted into one of the treatment groups, and will receive your study drug. For some trials, there is a chance you'll receive a placebo. Across psoriasis trials in Austin, 42% of clinical trials have a placebo. Typically you'll be required to check-in with the clinic every month or two. The average trial length in this city for psoriasis patients is 6 Months.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in getting approval for a specific condition. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. Phase 2 trials are those where the drug has some data showing safety in humans, but where effectiveness has typically only been shown in animals and non-human experiments. Phase 1 trials are the trials where we don't have safety data in humans. As a general rule, phase 3 trials are more promising than phase 2, and phase 2 trials are more promising than phase 1.

Where in Austin is research being conducted for psoriasis?

Austin Regional Clinic is conducting clinical trials for psoriasis. These trials are taking place in the northern part of Austin, with approximately 2 trials ongoing as of 2023.

What promising new drugs are being tested?

In Austin, psoriasis research is focusing on treatments like Monoclonal Antibodies and Janus Kinase (JAK) Inhibitors. Notable drugs being studied include Guselkumab, Ixekizumab, and Upadacitinib.